arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Global Pharmaceutical and Biotechnology Conference 2020

London |
Speakers include:
Sarah Neville

Sarah Neville

Financial Times

Hannah Kuchler

Hannah Kuchler

Financial Times

David Redfern

David Redfern

GlaxoSmithKline

Overview

The global pharma industry is at a turning point in its transformation. After years of research, the field of advanced cell and gene therapies is achieving new landmarks, and the reality of curative therapies is here. The focus on molecular targets is opening up new possibilities for research, with the innovations which have transformed oncology in recent years making inroads in other diseases. Meanwhile the innovation system which supports new science is also evolving. With much of the advanced science now emerging from fleet-of-foot small pharma and emerging biotech, the power structures of the industry are also in flux. Significant changes will be needed to face the coming innovations in technology, pricing, manufacturing and personalised therapies, all of which present unique challenges to pharma companies' current economic and business models. 

Entitled ‘Transforming the Pharma Business for Growth’, the conference will feature an outstanding line-up of speakers sharing their insights, ideas and expertise on topics to include the increasingly complex and uncertain political and pricing environment, manufacturing as the new competitive edge for pharma, and the real-life impacts of AI and advanced technologies in R&D.

fallback
fallback Add to my Calendar 11/09/2020 12:00:0011/10/2020 17:21:00trueFT Global Pharmaceutical and Biotechnology Conference 2020The global pharma industry is at a turning point in its transformation. After years of research, the field of advanced cell and gene therapies is achieving new landmarks, and the reality of curative therapies is here. The focus on molecular targets is opening up new possibilities for research, with the innovations which have transformed oncology in recent years making inroads in other diseases. Meanwhile the innovation system which supports new science is also evolving. With much of the advanced science now emerging from fleet-of-foot small pharma and emerging biotech, the power structures of the industry are also in flux. Significant changes will be needed to face the coming innovations in technology, pricing, manufacturing and personalised therapies, all of which present unique challenges to pharma companies' current economic and business models. Entitled ‘Transforming the Pharma Business for Growth’, the conference will feature an outstanding line-up of speakers sharing their insights, ideas and expertise on topics to include the increasingly complex and uncertain political and pricing environment, manufacturing as the new competitive edge for pharma, and the real-life impacts of AI and advanced technologies in R&D.FT-Global-Pharmaceutical-and-Biotechnology-Conference-2020832c11be7fa262ddb791370db172bbd9MM/DD/YYYY

video

2019 Conference Highlights, by Sarah Neville

Sarah Neville

fallback

What attendees had to say about their 2019 experience

What attendees had to say about their 2019 experience 

"An incredibly well-curated event. A great combination of thought-provoking discussions and networking."

"A good opportunity to gain insight into the current challenges in healthcare, pharma and biotech industry."

"If you want a glimpse into the future of the pharmaceutical industry, this is the conference to attend."

"You can always expect fantastic line-ups of speakers from this event."

"The FT Live conference is one of the premier biopharma events in the UK."

fallback

Agenda - 9th Nov

  • 12:00pm
    Lunch and Registration
  • 1:00pm
    Opening Remarks from the Chair

    Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 1:05pm
    Keynote Address/Interview
  • 1:20pm
    Panel: Oncology and Beyond - Reshaping the Pharma Pipeline for Growth

    How sustainable is the industry’s current focus on oncology and rare diseases? Oncology and rare diseases account for the largest share of pharma pipeline spend, and continuing innovation in the field of genomics, immunology and beyond offer the potential of a continued healthy pipeline of products in the future. Yet, as the area becomes increasingly overcrowded, there are early signs of a shift as pharma companies consider a more diversified approach. What are the next generation of innovations in oncology? Beyond oncology, what will be the new big areas of pipeline focus? Will investors support a more diversified approach? Where is the science and innovation taking us? What are the trends in molecular targeting, and where might the molecular targeting which has transformed oncology happen next? How might the move away from the current focus on single diseases to molecular targets transform R&D, the structure of the pharma business, and way we treat patients?

  • 2:10pm
    Keynote Interview
  • 2:25pm
    Networking Coffee Break
  • 2:45pm
    Keynote Interview/Address
  • 3:00pm
    Panel: The Changing Power Structure of the Industry - How is Pharma Innovation Model Evolving?

    The dynamics of industry innovation are changing. Where once pharma companies held the proprietary knowledge, data and many of the other critical functions to bring drugs to market, the innovation landscape is now energised by leading science coming from smaller pharma and early-stage and emerging biotech, academia, incubators who are infrastructure-light, and are proving light of foot in moving from science to translation when they spot an opportunity. Pharma companies also face strong competition from big tech and an array of AI-driven drug development companies bringing high-tech expertise to both R&D and the patient focused business of prevention and disease management. Yet pharma still brings the advantages of scale. and big pharma’s increasingly close integration with the wider healthcare industry should stand it in good stead as the competitive landscape evolves.

    • How is the dynamic between pharma and biotech changing? How will biotechs innovate and grow? How successful will they be in efforts to carve out an independent future or will they remain the ‘small fish’ to be swallowed by big pharma?
    • Should pharma spend less on research, given the shift, or does scale still matter in R&D?
    • Given the changing dynamic, how will pharma create the networks/ecosystems which will provide the funnel of pipeline products for the future, and how does pharma ensure it is a partner of choice for biotech?
    • Will big tech ‘eat pharma’s lunch’ or will success be limited to specific activities? To what extent will data become the key ingredient of success going forward?
    • How will regulators/ the regulatory approval process define success/the balance of power going forward?
  • 3:50pm
    Keynote Interview/Address
  • 4:10pm
    Keynote Panel
  • 5:00pm
    Closing Remarks from the Chair
  • 5:05pm
    Close of Day One

Agenda - 10th Nov

  • 9:00am
    Opening Remarks from the Chair
  • 9:05am
    Presentation/Panel: The US Presidential Election - the Implications for Pharma
  • 9:30am
    Presentation/Keynote Interview: Innovation and Lower Drug Prices - Can they Co-Exist?
  • 9:45am
    Panel: The Million Dollar Question - How do we Pay for Cures? / Paying for Cures

    A ‘toolkit’ of innovative reimbursement models to pay for high cost, potentially curative drugs advancing from advances from the realms of immune-oncology and cell and gene therapies is emerging, but implementation challenges remain. With many more such drugs set to make their way to the clinic in the years ahead, urgent solutions will need to be found.
    What constitutes a 21st century payment system?

    • How do you value cures? What is the current thinking and the way ahead?
    • Will stakeholders reach agreement on standardised measurements of value?
    • Are value-based payments (VBP) merely delaying the inevitable - the need to lower start prices?
    • What are the challenges pharma companies are experiencing under the new payment contracts? How is the infrastructure e.g. support services, evolving to support them?
    • Beyond VBP, what are the other proposed payment models e.g. reinsurance, other solutions?
  • 10:30am
    Keynote Address/Interview
  • 10:45am
    Networking Coffee Break
  • 11:05am
    Panel: Manufacturing - The New Competitive Edge for Pharma

    As the complexity of drugs increases and the race heats up to bring the next generation of advanced cell and gene therapies to market, manufacturing capacity and prowess can be the make or break of bringing these therapies to patients. Regulators are expected to take account of manufacturing availability in approval processes going forward, and innovations in manufacturing will be key to reducing tackling capacity constraints, reducing the high costs, and hence limiting pressure on the prices of these drugs going forward. Ingenuity in manufacturing will need to be as cutting edge as the therapies themselves.

    • What are the innovations which will transform pharma manufacturing in the years ahead? What will the pharma factory of the future look like?
    • To what extent might manufacturing put a break on the delivery of advanced therapies to market?
    • What do current trends (e.g. CDMO production of drugs for own account; pharma acquiring CDMOs, Biotech collaborations with CDMOs) tell us about how the industry might reshape in the years ahead?
    • What is the role of the cell and gene therapy clusters / the emerging CGT ecosystem(s)?
  • 11:45am
    Keynote Interview/Presentation
  • 12:00pm
    Panel: Unravelling Data Ownership

    Access to good quality, patient-generated data is increasingly important and valuable to pharma companies, with high hopes for the role it can play in drug discovery, behavioural interventions and outcomes optimisation. However, the current ‘free for all’ with regards to date ownership which has seen confidential patient data sold to third parties without patient consent, and the realisation of that ‘anonymised data’ can be relatively easily be reidentified has brought calls for new ways to keep the data flowing, while addressing growing public concern. How is the world of data rights with regards to health information evolving? Is health data a public good? Should patients be paid for sharing data, and how can patient data sharing best be incentivised? What are the proposed solutions to enable patients to have greater control of their data, including the role of data custodians and other approaches?

  • 12:40pm
    Keynote Interview/Presentation
  • 12:55pm
    Networking Lunch
  • 1:55pm
    Panel: How Technology is Transforming R&D

    Pharma companies are using technologies to include advances in AI, functional genomics and other innovations to take a patient focused approach, to accelerate the pace of medicines discovery, to reduce the costs of clinical trials and deliver drugs to patients faster. And advances in the use of technology in R&D is receiving a boost with regulators including the FDA releasing guidelines on the use of RWE/RWD, and with their growing acceptance of novel patient-centred and digital endpoints in the approval of new drugs.

    • What are the ways in which AI and big data are making/will make a meaningful impact in R&D, and where is pharma on its AI /data journey? Including validity and building patient and regulators’ trust, what are the limitations of AI and use of big data in R&D, and how can they be addressed? What challenges are pharma companies experiencing along with way?
    • How successful will pharma companies be ultimately in finding new ways to apply AI to big data sets to discover new drugs, given the complexity of the underlying biology?
    • What is emerging best practice and the ROI of patient centricity efforts in pharma R&D?
    • Digital endpoints: How is the science of clinical trials and the new models, including Virtual Clinical Trials (VCTs), evolving? What have been the experiences and the challenges?
  • 2:50pm
    Panel: Neurology

    In the words of one leading industry executive, ‘Neurology has the potential to be in the 2020s what oncology has been in the last decade’. Much hope is invested in the area of the largest unmet needs - in drugs for dementia, and for Alzheimer’s in particular, as investors the industry awaits the potential arrival of the first approved drugs in decades. However, there is considerable innovation emerging elsewhere too, as greater understanding of brain biology and functioning, new ways of overcoming the blood-brain barrier, the application of other areas of novel research including cell and gene technologies and the burgeoning area of neurotech transform the potential for new drugs in this important therapeutic area.

    • What are the new developments challenging the gloomy narrative in Alzheimer’s research? What is the potential of advanced in regenerative medicine and other innovations to transform prospects?
    • Opportunities for new approaches to pain management
    • Beyond SSRIs-what’s next for neuropsychiatry and the treatment of depression?
    • Prospects for markets in medicinal cannabis and psychedelics. How are issues such as evidence, access being addressed, and can pharma successfully monetise?
    • What are the new frontiers in neurotechnology, and what therapies and products might we see emerging in the coming years?
  • 3:30pm
    Networking Coffee Break
  • 3:50pm
    Keynote Interview/Address
  • 4:05pm
    Panel: Women’s Health

    Awareness is growing in this critical area of healthcare. Women’s healthcare has been largely underserved and underfunded, yet there is significant scope for innovation. Issues to include stigma, the challenge of attracting scientists to this specialisation have impeded market growth, yet the market opportunity is significant. Women account for half the global population and they are the leading decision makers in term of family health and healthcare spend. The health and pharma industry are rallying to the cause, and the field of femtech, for instance, has expanded significantly in recent years. As the issue of under representation of women in drug trials hits the headlines, meanwhile, the business of women’s health is gradually moving to the spotlight. What are the emerging opportunities and how are early pioneers in this market addressing the market?

  • 4:45pm
    Panel: Coronavirus - A 21st Century Case Study of Pharma and Health

    From the application of leading-edge genomic science and the innovative use of digital technologies including AI, drones and telehealth in tracking and monitoring the disease, to the debate over the means of incentivising pharma companies to create medicines for vital, but often lossmaking treatments - the recent coronavirus outbreak presents a microcosm of the challenges facing the industry. What have been the lessons learned from the experience? How has the industry applied all the ingenuity and progress in drug development, regulation, cross-industry collaboration and technology advances of recent years to address emerging challenges? Has the global response been adequate? Has the industry stepped up to the plate, and has its reputation been enhanced in the process? Or does the widespread perception of the industry remain one of ‘profits over patients’?

  • 5:20pm
    Closing Remarks from the Chair

CHAIR (2)

Sarah Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. 

Hannah Kuchler

Hannah Kuchler

US Pharma and Biotech Correspondent
Financial Times

Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York.  Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.

ADVISORY BOARD (9)

David Redfern

David Redfern

Chief Strategy Officer
GlaxoSmithKline

David Redfern was appointed Chief Strategy Officer of GSK in May 2008.   He is a member of the Corporate Executive Team and reports to the CEO. Mr Redfern is also Chairman of ViiV Healthcare Ltd.   ViiV was created in 2010 and is a joint venture between GSK, Pfizer and Shionogi and focuses specifically on the research, development and commercialisation of medicines to treat HIV.  In February 2015, Mr Redfern was appointed a non–executive director of Aspen Pharmacare Holdings Ltd., a South African listed healthcare company. Previously, he was responsible for the leadership of GSK’s business in Northern Europe from 2005-2008 and Central Europe from 2002-2005.  He joined Glaxo in 1994 in finance and progressed through a series of finance roles before becoming Finance Director of the European business in 1999.  Prior to Glaxo, Mr Redfern worked for PWC in London, Zambia and Paris.   

Francesca Wuttke

Francesca Wuttke

Chief Digital Officer
Almirall

Francesca Domenech Wuttke, PhD is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end company-wide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall. Dr Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 20 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organisations including start-ups, consulting, large and specialty pharma as well as academia. Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr  Wuttke led Almirall´s Corporate Development Strategy team to transact on both medical device and pharma M&A opportunities with a new and targeted focus for the company. Prior to that, Dr Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organisation as well as managing the strategy and commercialisation for the existing portfolio of cell therapy assets. Dr Wuttke holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.

Simon Sturge

Simon Sturge

CEO
Kymab
Virginia Acha

Virginia Acha

Executive Director-Global Regulatory Policy, R&D Innovation Centre
MSD

Virginia (Ginny) Acha has worked in industry and academia throughout her career, combining interests in science policy research and innovation performance within and across organisations.  She recently joined MSD to lead regulatory policy efforts for innovation that will lead to better treatment for patients in Europe, the Middle East, Africa and Asia.  In particular, she is supporting work on real world evidence and integrated evidence generation. Before joining MSD, Dr Acha was the senior spokesman for the industry in the UK for research, medical and innovation policy.  She was responsible for ABPI’s work on Brexit for the life sciences sector.  Previously, Dr Acha worked for Amgen in global regulatory policy and for Pfizer working on policy development in science and innovation in healthcare. 

Lisa  Anson

Lisa Anson

CEO
Redx Pharma

Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed in June 2018. She held the post of President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Ms Anson held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams. She joined Zeneca Pharmaceuticals (USA) in 1998 as a business development manager. Prior to this she worked for Salick Health Care (now Aptium), a California based cancer disease management company. Her first position upon graduating from university was with KPMG in London as a management consultant

Ms Anson is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.

Ms Anson holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. 

Steve Alperin

Steve Alperin

CEO and Co-Founder
SurvivorNet

Steve Alperin is the CEO of SurvivorNet, the new definitive source for information about cancer. Mr Alperin has a 20 year track record creating large-scale online content platforms and award winning television programs. At ABC News, Mr Alperin ran the digital content operation. Prior to that, he worked side-by-side with Peter Jennings for nearly a decade as the Head Writer and producer for ABC’s World News Tonight. Mr Alperin also served as the Chief Business Officer of the youth media company Vocativ, producing programming for major companies including NBC Universal and Showtime. He has been recognised with numerous awards for excellence in journalism including The DuPont, Edward R. Murrow, and Writers Guild Awards. He holds an MBA from Columbia and a BA in Government from Harvard.

Hanno Ronte

Hanno Ronte

Partner
Monitor Deloitte

Hanno Ronte is a Partner at Monitor Deloitte in London with 25 years of consulting experience.  His projects have focused on corporate strategy, business unit strategy, competitive response, marketing strategy and capability building as well as cost reduction and optimisation projects.  He has extensive experience in the healthcare and life science sector, working at board, business unit and brand level to drive change and impact in his clients.  He frequently facilitates senior executive meetings to drive decisions and create alignment.  Mr Ronte has a particular interest in how the life science industry has to increasingly operate across government, healthcare providers and payors. Prior to the merger with Deloitte in Jan 2013, Mr Ronte was part of the European management team for the Monitor Group, a member of the global Partnership Election Committee, and the head of the London office.  He has been at Monitor for 15 years, prior to which he worked at Braxton Associates / Deloitte Consulting. Mr Ronte has spoken at a number of international conferences on Real World Evidence and the future of the life science industry.  He has also co-authored a number of Deloitte Centre for Health Solutions publications. Mr Ronte holds a First Class BA Honours Degree in Economics from Jesus College Cambridge and an MBA with Distinction from London Business School.  He graduated as the top of his class from Vienna International School with an IB.

Christian Hebenstreit

Christian Hebenstreit

Senior Vice President and General Manager
Medidata
Andy Garrett

Andy Garrett

Executive Vice President, Scientific Operations
ICON

Andrew Garrett is Executive Vice President Scientific Operations at ICON, responsible for strategic direction and operational execution of ICON’s Global Scientific Operations. He was Chair and Founder of the Royal Statistical Society’s (RSS) Data Science Section having previously been VP/Honorary Secretary of the organisation, and Chair of its Long Term Strategy Group. He was previously a Board member of the UK’s Administrative Data Research Network and is currently a member of UKSA’s Research Accreditation Panel that oversees the approval of research projects in accordance with the Digital Economy Act 2018. He has worked extensively in the area of rare diseases and has a portfolio of published papers on the topics of non-inferiority trials, subgroup analysis, data transparency and modelling and simulation. Dr Garrett has a BSc in Economics, an MSc in Medical Statistics and a PhD in Applied Statistics.

fallback

WHY ATTEND?

  • Learn how a focus on molecular targets will transform R&D, the pharma business models and the treatment of patients
  • Discover how the pharma-biotech dynamic is changing and what it means for pharma partnering and deal making
  • Share perspectives on how pharma can build on its increasing integration with the broader healthcare industry and scale in R&D to win in an ever more competitive industry landscape
  • Debate the big issues - how do we pay for cures?
  • Hear first-hand how manufacturing is the new competitive edge for pharma
  • Gain insights into emerging opportunities in neurology and women’s health
  • Deep dive into our experiences and learnings from the coronavirus outbreak - did the industry step up to the plate? And how have all the ingenuity and advances in science and technology of recent years played out to address the crisis?
fallback

WHO ATTENDS?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.

The FT Global Pharmaceutical and Biotechnology Conference will be attended by:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic and medical device
  • CROs
  • Healthcare providers and insurers
  • Government healthcare departments, HTA’s and drug regulators
  • IT, big data and analytics providers
  • Health economists
  • Healthcare investment bankers, private equity
  • Patient representatives and NGOs
fallback

ATTENDING COMPANIES IN 2019

Sanofi • Roche • Bayer • AstraZeneca • Novartis • Merck Group • GlaxoSmithKline • Pfizer • Johnson & Johnson • Gilead Sciences •  Abbvie •  Allergan •  Teva Pharmaceutical Industries •  Celgene •  Astellas Pharma •  UCB Biopharma •  Bayer AG, Pharmaceuticals •  Sandoz •  BeiGene •  Ipsen •  Kymab •  Verona Pharma •  AstraZeneca Poland •  Teva Italia •  Acacia Pharma Group •  MNK Pharma, and many others.

fallback

SPONSORSHIP OPPORTUNITIES

  • Gain access to 350 Senior Executives from the International Pharmaceutical Industry, who will be attending the event;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames
Commercial Manager, Global Industries
M: +44 (0)791 329 2038
E: joe.hames@ft.com

fallback

Global sponsor (1)

About Life Sciences and Health Care at Deloitte

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

Global Clinical Research Partner (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 40 countries and has approximately 14,500 employees. For further information please visit www.iconplc.com  Follow @iconplc on Twitter.

LEAD SPONSORS (3)

Livongo offers a whole person platform that empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention, and behavioral health. Livongo pioneered the new category of Applied Health Signals to silence Noisy Healthcare™. Our team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized and timely health signals. The Livongo approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions.

At Spencer Stuart, we know how much leadership matters. We are trusted by global healthcare, biopharmaceutical and leading biotechnology organizations around the world to help them make the senior-level leadership decisions that have a lasting impact on their enterprises. Through our executive search, board and leadership advisory services, we help build and enhance high-performing teams for select clients ranging from major multinationals to emerging companies to nonprofit institutions. Privately held since 1956, we focus on delivering knowledge, insight and results through the collaborative efforts of a team of experts —now spanning more than 60 offices, over 30 countries and more than 50 practice specialties. Boards and leaders consistently turn to Spencer Stuart to help address their evolving leadership needs in areas such as senior-level executive search, board recruitment, board effectiveness, succession planning, in-depth senior management assessment, employee engagement and many other facets of culture and organizational effectiveness. For more information on Spencer Stuart, please visit www.spencerstuart.com.

Associate Sponsors (2)

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,400 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.Medidata is a registered trademark of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèm

TraceLink is a network-based platform company that leverages its digital supply network and digital network platform to bend the supply chain around the patient. Through its industry-leading digital supply network, the TraceLink Digital Network Platform can enable seamless data sharing and process orchestration across the entire healthcare industry, enabling the creation of a real-time, patient-driven supply network to ensure that every patient gets the medicines they need, when they need them, safely and securely.

PRESENTED BY (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

VENUE

Royal Lancaster
Lancaster Terrace
London W2 2TY

United Kingdom

Tel: +44 207 551 6000

fallback

CONTACTS

FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times
Joe Hames
Sponsorship & Exhibitor Opportunities
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Alexsandra Silva
Media Partner and Press Enquiries
Financial Times